Joel Greenblatt's CORT Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 17,352 shares of Corcept Therapeutics Incorporated (CORT) worth $603,850, representing 0.00% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in CORT, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2018, adding 66,533 shares. Largest reduction occurred in Q4 2017, reducing 48,616 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Corcept Therapeutics Incorporated (CORT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Corcept Therapeutics Incorporated (CORT) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -10 | Reduce 0.06% | 17,352 | $34.80 |
| Q3 2025 | +50 | Add 0.29% | 17,362 | $83.11 |
| Q2 2025 | -111 | Reduce 0.64% | 17,312 | $73.40 |
| Q1 2025 | -1,714 | Reduce 8.96% | 17,423 | $114.22 |
| Q4 2024 | +523 | Add 2.81% | 19,137 | $50.39 |
| Q3 2024 | -6,341 | Reduce 25.41% | 18,614 | $46.28 |
| Q2 2024 | -13,717 | Reduce 35.47% | 24,955 | $32.49 |
| Q1 2024 | +21,009 | Add 118.94% | 38,672 | $25.19 |
| Q4 2023 | -73 | Reduce 0.41% | 17,663 | $32.48 |
| Q3 2023 | -4,066 | Reduce 18.65% | 17,736 | $27.24 |
| Q2 2023 | -7,405 | Reduce 25.35% | 21,802 | $22.25 |
| Q1 2023 | -14,458 | Reduce 33.11% | 29,207 | $21.66 |
| Q4 2022 | +5,510 | Add 14.44% | 43,665 | $20.31 |
| Q3 2022 | -9,166 | Reduce 19.37% | 38,155 | $25.63 |
| Q2 2022 | -2,119 | Reduce 4.29% | 47,321 | $23.77 |
| Q1 2022 | +594 | Add 1.22% | 49,440 | $22.51 |
| Q4 2021 | +30,279 | Add 163.08% | 48,846 | $19.80 |
| Q3 2021 | +3,188 | Add 20.73% | 18,567 | $19.66 |
| Q2 2021 | -1,373 | Reduce 8.20% | 15,379 | $21.98 |
| Q1 2021 | -9,811 | Reduce 36.93% | 16,752 | $23.82 |
| Q4 2020 | -16,822 | Reduce 38.77% | 26,563 | $26.16 |
| Q3 2020 | +14,374 | Add 49.55% | 43,385 | $17.40 |
| Q2 2020 | -43,332 | Reduce 59.90% | 29,011 | $16.82 |
| Q1 2020 | -5,791 | Reduce 7.41% | 72,343 | $11.89 |
| Q4 2019 | +29,674 | Add 61.23% | 78,134 | $12.09 |
| Q3 2019 | -27,727 | Reduce 36.39% | 48,460 | $14.14 |
| Q2 2019 | -39,642 | Reduce 34.22% | 76,187 | $11.14 |
| Q1 2019 | -6,964 | Reduce 5.67% | 115,829 | $11.74 |
| Q4 2018 | +66,533 | Add 118.26% | 122,793 | $13.36 |
| Q3 2018 | -13,761 | Reduce 19.65% | 56,260 | $14.02 |
| Q2 2018 | +49,309 | Add 238.07% | 70,021 | $15.72 |
| Q1 2018 | +2,878 | Add 16.14% | 20,712 | $16.46 |
| Q4 2017 | -48,616 | Reduce 73.16% | 17,834 | $18.06 |
| Q3 2017 | +6,793 | Add 11.39% | 66,450 | $19.29 |
| Q2 2017 | +47,968 | Add 410.37% | 59,657 | $11.80 |
| Q1 2017 | -26,321 | Reduce 69.25% | 11,689 | $10.95 |
| Q4 2016 | +17,102 | Add 81.80% | 38,010 | $7.26 |
| Q3 2016 | +5,884 | Add 39.16% | 20,908 | $6.50 |
| Q2 2016 | +15,024 | New Buy | 15,024 | $5.46 |
| Q1 2016 | -17,347 | Sold Out | 0 | $0.00 |
| Q4 2015 | +126 | Add 0.73% | 17,347 | $4.96 |
| Q3 2015 | +17,221 | New Buy | 17,221 | $3.77 |
Joel Greenblatt's Corcept Therapeutics Incorporated Investment FAQs
Joel Greenblatt first purchased Corcept Therapeutics Incorporated (CORT) in Q3 2015, acquiring 17,221 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Corcept Therapeutics Incorporated (CORT) for 42 quarters since Q3 2015.
Joel Greenblatt's largest addition to Corcept Therapeutics Incorporated (CORT) was in Q4 2018, adding 122,793 shares worth $1.64 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 17,352 shares of Corcept Therapeutics Incorporated (CORT), valued at approximately $603,850.
As of the Q4 2025 filing, Corcept Therapeutics Incorporated (CORT) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Corcept Therapeutics Incorporated (CORT) was 122,793 shares, as reported at the end of Q4 2018.